Peregrine Capital Management LLC Sells 208,811 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Peregrine Capital Management LLC decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 25.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 606,233 shares of the biotechnology company’s stock after selling 208,811 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.26% of ADMA Biologics worth $6,778,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Viewpoint Capital Management LLC increased its holdings in shares of ADMA Biologics by 18.6% during the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 2,416 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in shares of ADMA Biologics by 20.2% during the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 4,367 shares in the last quarter. CWM LLC increased its holdings in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of ADMA Biologics by 9.2% during the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 4,570 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the first quarter valued at $31,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.09 on Friday, hitting $17.31. The stock had a trading volume of 3,191,482 shares, compared to its average volume of 3,050,170. The stock has a market cap of $4.01 billion, a price-to-earnings ratio of -865.50 and a beta of 0.55. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. The business’s 50-day simple moving average is $13.86 and its two-hundred day simple moving average is $9.62. ADMA Biologics, Inc. has a 52-week low of $3.06 and a 52-week high of $18.48.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The business’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period last year, the firm posted ($0.02) earnings per share. As a group, research analysts predict that ADMA Biologics, Inc. will post 0.35 earnings per share for the current year.

Insider Activity

In other news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Insiders have sold a total of 557,900 shares of company stock valued at $9,129,891 in the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ADMA. Cantor Fitzgerald raised their price target on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Raymond James increased their price objective on ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. HC Wainwright increased their price objective on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Mizuho increased their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.